Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.77 |
| ▸ | FLT1 | P17948 | 1/20 | 0.77 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | FBP1 | P09467 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.71 |
| ▸ | TEK | Q02763 | 1/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17520362 | 1.00 | EGFR (1.00) | EGFRKDRFGFR1FLT1AURKA | |
| SCHEMBL11683 | 0.96 | EGFR (0.92) | EGFRKDRFGFR1FLT1AURKA | |
| SCHEMBL18979111 | 0.96 | EGFR (0.92) | EGFRKDRFGFR1FLT1AURKA | |
| SCHEMBL19220785 | 0.90 | EGFR (0.82) | EGFRKDRFGFR1FLT1AURKA | |
| SCHEMBL12856430 | 0.89 | EGFR (0.80) | EGFRKDRFGFR1FLT1ERBB2 | |
| SCHEMBL7451584 | 0.87 | FLT1 (1.00) | EGFRKDRFGFR1FLT1PDGFRB | |
| Hydrochloric Acid SCHEMBL7455267 | 0.86 | FLT1 (0.98) | EGFRKDRFGFR1FLT1PDGFRB | |
| SCHEMBL19220767 | 0.86 | EGFR (0.76) | EGFRKDRFGFR1FLT1ERBB2 | |
| SCHEMBL13524614 | 0.85 | EGFR (0.87) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL30520472 | 0.85 | EGFR (0.87) | EGFRKDRAURKAERBB2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2634178-B1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | CHINESE ACAD INST CHEMISTRY (CN) | 2016-08-24 | — | — | EP | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2634178-A1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | Institute Of Chemistry, Chinese Academy Of Sciences (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| EP-1853300-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | Genentech, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006089015-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 34/4885FGFR1 47/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | EGFR 1/4885KDR 50/4885FGFR1 1140/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 34/4885FGFR1 47/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885KDR 33/4885FGFR1 19/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885KDR 33/4885FGFR1 19/4885 |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | MAP3K21, MAP3K15, MAP3K14 | EGFR 225/4885KDR 2894/4885FGFR1 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.